How HAYA Turned A Fringe RNA Modality Into A Lilly Deal And Moved It Into The Clinic
HAYA Therapeutics CEO Samir Ounzain, a 2026 In Vivo Rising Leader, is testing his 15-year conviction that the genome's "junk DNA" can treat chronic disease, moving lead lncRNA drug HTX-001 into the clinic.
In Vivo - July 22, 2026

FDA Invites Digital Health Industry To Apply For Grants Supporting Drug Development Research
The FDA is offering grants of up to $1.1m each to fund research into using digital health tools across the drug development pipeline. Medtech firms are among those eligible to apply, with the deadline Aug. 20.
Medtech Insight - July 22, 2026

European Biotech At A Crossroads: How Can It Stay Competitive? Video Podcast
European biotech leaders from Forbion, Complement Therapeutics and argenx discuss the challenges facing the region’s companies and how a new industry initiative to boost financing and market competitiveness could help build the next generation of breakthrough firms.
Scrip - July 22, 2026

J&J Gets FDA Nod For General Surgery Robot It Hopes Will Drive Growth
De novo approval for Ottava system lets Johnson & Johnson launch its “differentiated” surgical robot into a competitive market.
Medtech Insight - July 22, 2026

Probiotic Purchasing Lagging Behind Gut Health Interest
A recent PrecisionBiotics survey finds UK consumers are increasingly focused on their gut health, yet only 11% take a probiotic and 65% have never heard of the gut-brain axis.
HBW Insight - July 22, 2026

Pierre Fabre Doubles Down On Women’s Health With MiYé Investment
French dermo-cosmetics giant Pierre Fabre is expanding its bet on women's hormonal health, lifting its MiYé stake to 38% to fund a pharmacy network push and new product development.
HBW Insight - July 22, 2026

Celldex Stands By Barzolvolimab in CSU After Prurigo Nodularis Miss
The biotech is discontinuing barzolvolimab in prurigo nodularis after a Phase II miss but believes it carries no read-through to its pivotal CSU program.
Scrip - July 22, 2026

IMUNON Reports Preliminary Phase II MRD Data As Phase III Ovarian Cancer Trial Advances
Early biomarker signals from IMNN-001 strengthen the scientific rationale for IMUNON's pivotal Phase III ovarian cancer trial, with future data expected to determine whether the findings translate into clinical benefit.
Scrip - July 22, 2026

Novartis CEO Praises Japan And Blasts Germany Over Pricing
Vas Narasimhan has reiterated concerns about what he perceives as the German government's innovation-unfriendly policies but says Japan is going in the right direction.
Scrip - July 22, 2026

Novo Nordisk Announces Cheaper Ozempic Copy In South Africa
As generic semaglutide competition starts to line up, Novo Nordisk launches a cheaper copy of its GLP-1 blockbuster for diabetes.
Generics Bulletin - July 22, 2026

Trump Announcement Of Generic Tariffs Returns Industry To Uncertainty
Donald Trump’s bombshell announcement that generics imported into the US will face 100% tariffs from 2028 – rising to 200% in 2029 – returns the industry to a state of uncertainty that many had thought was behind them.
Generics Bulletin - July 22, 2026

FDA Nod Deepens Looming Challenge To Lynparza Franchise
Natco’s tentative FDA approval moves generic olaparib closer to market, but a 2027 trial, unchallenged compound patent and expanding Hatch-Waxman litigation continue to cloud launch timing.
Generics Bulletin - July 22, 2026

Opdivo’s Biosimilar Challenge Spreads From India To Russia
Biocad’s Nivocad approval makes Russia only the second market after India to clear a nivolumab biosimilar, widening competitive pressure on Bristol Myers Squibb’s Opdivo.
Generics Bulletin - July 22, 2026

Cancer Diagnostics Breached At Abbott As 2026 Medtech Cyberattack Run Continues
Abbott is investigating unauthorized access to a limited number of internal systems within its Cancer Diagnostics business, with no impact on operations or patient care. It is still determining what information was accessed and is separately probing a claimed intrusion into its LabCentral portal.
Medtech Insight - July 22, 2026

Driving adoption in community-based trials: Why flexibility isn’t enough
Redesigning Reach: Community-based Research In Action
Scrip - July 22, 2026

The Next Era Of Oncology Biosimilars
Assessing the scientific, regulatory and commercial forces shaping future opportunities
Generics Bulletin - July 22, 2026

As JCAs Reach Orphan Drugs, Developers Face A 2028 Deadline And No Fix In Sight
Concerns about whether the EU Joint Clinical Assessment system is appropriate for orphan drugs remain but change to the system looks unlikely before the European Commission reviews the overarching Health Technology Assessment Regulation in 2028.
In Vivo - July 22, 2026

Serabelisib Set To Join PI3K? Fray As Kaken Makes Japan Vascular Filing
US-originated asset has had a complex development history but takes a key step towards possible commercialization for the high-need indication of vascular malformations.
Scrip - July 22, 2026

Brands Should ‘Reinterpret,’ Not Imitate, K-Beauty For Local Markets – NielsenIQ
NielsenIQ says beauty brands can successfully leverage the global K-Beauty boom by adapting the innovation, ingredient and marketing strategies behind Korean beauty rather than simply copying products.
HBW Insight - July 22, 2026